Skip to main content

Advertisement

Log in

The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background: The aim of this study was to determine any correlation between the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines and the matrix metalloproteinase 9 (MMP-9) expression in primary colorectal cancer tissues. Patients and Methods: The data on 307 patients with colorectal cancer at stage II or III, who underwent potentially curative resection with lymphadenectomy, were reviewed. Of these, 188 received postoperative administration of oral fluoropyrimidines such as UFT and 5′-DFUR (chemotherapy group), while the other 119 patients underwent surgery alone (surgery-alone group). Immunostaining for MMP-9 was performed using surgical specimens of all 307 primary tumors and 18 recurrent tumors. Results: Overall, MMP-9 was positively expressed in the primary tumor in 44% of patients. Multivariate analysis revealed that the MMP-9 expression was a worse prognostic factor with a second highest hazard ratio for recurrence. The disease-free survival rate in the chemotherapy group was significantly higher than that in the surgery-alone group. However, no significant difference in disease-free survival rate between the two groups was found in patients with a tumor positive for MMP-9. There was a strong positive correlation of MMP-9 expression between the primary tumors and the recurrent liver or lung tumors. Conclusions: The efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines such as UFT and 5′-DFUR may not be as great for patients with a tumor positive for MMP-9 having a greater risk to postoperative recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. 1. Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer Statistics. CA Cancer J Clin 50:7–33

    Article  PubMed  CAS  Google Scholar 

  2. 2. *International Multicentric Pooled Analysis of Colon Cancer Trials (IMPACT) investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345:939–944

    Article  Google Scholar 

  3. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A. *Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351

    Google Scholar 

  4. 4. Sakamoto J, Kato J, Nakazato H (2000) Adjuvant chemotherapy clinical trials against colorectal cancer in Japan. Jpn J Cancer Clin 46:1187–1195

    Google Scholar 

  5. 5. *Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum and the Meta-Analysis Group in Cancer (2004) Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 22:484–492

    PubMed  Google Scholar 

  6. Wolmark N, Wieand S, Lembersky B, Colangelo L, Smith R, Pazdur R (2004) A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22: 3508

  7. Twelves C, Wong A, Nowacki MP, McKendrick J, Van Hazel G, Douillard J-Y, Diaz-Rubio E, Cassidy J, Maroun J (2005) Updated efficacy findings from the X-ACT phase III trial of capecitabine vs. bolus 5-FU/LV as adjuvant therapy for patients with Dukes’ C colon cancer. Proc Am Soc Clin Oncol (abstract 3521)

  8. 8. Inuzuka K, Ogata Y, Nagase H, Shirouzu K (2000) Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. J Surg Res 93:211–218

    Article  PubMed  CAS  Google Scholar 

  9. 9. Ogata Y, Pratta MA, Nagase H, Arner EC (1992) Matrix metalloproteinase 9 (92-kDa) gelatinase/type IV collagenase) is induced in rabbit articular chondrocytes by cotreatment with interleukin 1β and a protein kinase C activator. Exp Cell Res 201:245–249

    Article  PubMed  CAS  Google Scholar 

  10. 10. Shirouzu K, Isomoto H, Morodomi T, Kakegawa T (1995) Carcinomatous lymphatic permeation: prognostic significance in patients with rectal carcinoma – a long term prospective study. Cancer 75: 4–10

    Article  PubMed  CAS  Google Scholar 

  11. 11. Shirouzu K, Isomoto H, Kakegawa T, Morimatsu M (1991) A prospective clinicopathologic study of venous invasion in colorectal cancer. Am J Surg 162:216–222

    Article  PubMed  CAS  Google Scholar 

  12. 12. *International Multicentric Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) investigators (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17:1356–1363

    Google Scholar 

  13. 13. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N (1993) CPT-11 Gastrointestinal Cancer Study Group: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909–913

    PubMed  CAS  Google Scholar 

  14. 14. Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, Nasca S, Nguyen TD, Paillot B, Raoul JL, Duffour J, Fandi A, Dupont-Andre G, Rougier P (1998) Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 16:2739–2744

    PubMed  CAS  Google Scholar 

  15. 15. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905–914

    Article  PubMed  CAS  Google Scholar 

  16. 16. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947

    PubMed  Google Scholar 

  17. 17. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282–2292

    PubMed  CAS  Google Scholar 

  18. 18. Seitz JF (2001) 5-fluorouracil/leucovorin versus capecitabine in patients with stage III colon cancer. Semin Oncol 28(suppl 1):41–44

    Article  PubMed  CAS  Google Scholar 

  19. Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, Bear HD, Atkins JN, Dimitrov NV, Glass AG, Fisher ER, Fisher B (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553–3559

    PubMed  CAS  Google Scholar 

  20. O’Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246–250

    PubMed  CAS  Google Scholar 

  21. Dancey JE, Freidlin B (2003) Targeting epidermal growth factor receptor—Are we missing the mark? Lancet 362:62–64

    Article  PubMed  CAS  Google Scholar 

  22. 22. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O’Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955–3964

    Article  PubMed  CAS  Google Scholar 

  23. 23. Stetler-Stevenson WG (1990) Type IV collageneses in tumor invasion and metastasis. Cancer Metastasis Rev 9:289–303

    Article  PubMed  CAS  Google Scholar 

  24. 24. Liotta L, Stetler-Stevenson WG (1990) Metalloproteinases and cancer invasion. Semin Cancer Biol 1:99–106

    PubMed  CAS  Google Scholar 

  25. 25. Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260–1270

    Article  PubMed  CAS  Google Scholar 

  26. 26. Zucker S, Conner C, DiMassmo BI, Ende H, Drews M, Seiki M, Bahou WF (1995) Thrombin induces the activation of progelatinase A in vascular endothelial cells: physiologic regulation of angiogenesis. J Biol Chem 270:23730–23738

    Article  PubMed  CAS  Google Scholar 

  27. 27. Jadhav U, Chigurupati S, Lakka SS, Mohanam S (2004) Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells. Int J Oncol 25:1407–1414

    PubMed  CAS  Google Scholar 

  28. 28. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C (2004) Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 48:411–424

    Article  PubMed  CAS  Google Scholar 

  29. 29. Yamauchi K, Ogata Y, Nagase H, Shirouzu K (2001) Inhibition of liver metastasis from orthotopically implanted colon cancer in nude mice by transfection of the TIMP-1 gene into KM12SM cells. Surg Today 31:791–798

    Article  PubMed  CAS  Google Scholar 

  30. 30. Oba K, Konno H, Tanaka T, Baba M, Kamiya K, Ohta M, Kaneko T, Shouji T, Igarashi A, Nakamura S (2002) Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166. Cancer Lett 175:45–51

    Article  PubMed  CAS  Google Scholar 

  31. 31. Goel R, Chouinard E, Stewart DJ, Huan S, Hirte H, Stafford S, Waterfield B, Roach J, Lathia C, Agarwal V, Humphrey R, Walsh W, Matthews S, Seymour L (2004) An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12–9566 in combination with 5-fluorouracil/leucovorin. Invest New Drugs 23:63–71

    Article  Google Scholar 

  32. 32. Eatock M, Cassidy J, Johnson J (2005) A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid. Cancer Chemother Pharmacol 55:39–46

    Article  PubMed  CAS  Google Scholar 

  33. 33. Maki H, Hojo K, Tanaka H, Sawada TY, Maekawa R, Yoshioka T (2002) Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11. Clin Exp Metastasis 19:519–526

    Article  PubMed  CAS  Google Scholar 

  34. 34. Ohta M, Konno H, Tanaka T, Baba M, Kamiya K, Oba K, Kaneko T, Syouji T, Igarashi A, Nakamura S (2001) Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer. Jpn J Cancer Res 92:688–695

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by a Grant-in-Aid for Scientific Research (C) (no.13671364) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yutaka Ogata.

Additional information

Ogata Y, et al. The efficacy of MMP inhibitor MMI270 against lung metastasis following removal of orthotopically transplanted human colon cancer. I J Cancer, 2005 (in press)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ogata, Y., Matono, K., Sasatomi, T. et al. The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Cancer Chemother Pharmacol 57, 577–583 (2006). https://doi.org/10.1007/s00280-005-0081-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-005-0081-9

Keywords

Navigation